Results 181 to 190 of about 25,328 (236)

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales

Infection and Drug Resistance, 2021
The spread of metallo-β-lactamase (MBL)-producing Enterobacterales worldwide without the simultaneous increase in active antibiotics makes these organisms an urgent public health threat. This review summarizes recent advancements in diagnostic and treatment strategies for infections caused by MBL-producing Enterobacterales.
Zackery Bulman, Yanqin Huang, Eric Wenzler   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas

International Journal of Antimicrobial Agents, 2021
The worldwide spread of carbapenem- and polymyxin-resistant Enterobacterales represents an urgent public-health threat. However, for most countries in the Americas, the available data are limited, although Latin America has been suggested as a silent spreading reservoir for isolates carrying plasmid-mediated polymyxin resistance mechanisms.
J. Rodríguez-Santiago, P. Cornejo-Juárez, J. Silva-Sánchez, U. Garza-Ramos   +3 more
openaire   +2 more sources

Rapid detection of Enterobacterales that produce carbapenemases

Diagnostic Microbiology and Infectious Disease, 2020
The rapid detection of carbapenemases among Enterobacterales in clinical laboratories is critical for management of patients, and infection prevention and control efforts.A study was designed to evaluate the performances of the RAPIDEC CARBA NP®, β-CARBA®, NG-Test CARBA 5®, modified carbapenem-inactivation method, and EDTA version (eCIM) assays against
Wilson W, Chan, Lorraine, Campbell, Diana, Doyle, Johann Dd, Pitout   +3 more
openaire   +2 more sources

Socioeconomic disparities in the prevalence of multidrug resistance in Enterobacterales

Infection Control & Hospital Epidemiology, 2023
AbstractWe examined the association between multidrug resistance and socioeconomic status (SES), analyzing microbiological and ZIP-code–level socioeconomic data. Using generalized linear models, we determined that multidrug resistance is significantly and persistently more prevalent in samples taken from patients residing in low-income ZIP codes versus
Dylan R. Brown, Heather I. Henderson, Laura Ruegsegger, James Moody, David van Duin   +4 more
openaire   +2 more sources

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

Microbial Drug Resistance, 2022
The objective of this study was to identify putative mechanisms contributing to baseline cefiderocol resistance among carbapenem-resistant Enterobacterales (CRE). We evaluated 56 clinical CRE isolates with no previous exposure to cefiderocol.
Patricia J. Simner, Stephan Beisken, Yehudit Bergman, Michael Ante, Andreas E. Posch, Pranita D. Tamma   +5 more
openaire   +2 more sources

Rapidly spreading Enterobacterales with OXA-48-like carbapenemases

Journal of Clinical Microbiology
Enterobacterales (mostly Klebsiella pneumoniae, Escherichia coli) with OXA-48-like carbapenemases (e.g., OXA-48, -181, -232, -244) are undermining the global efficiency of carbapenem therapy. In the Middle East, North Africa, and some European countries,
G. Peirano, J. Pitout
semanticscholar   +1 more source

World Health Organization priority antimicrobial resistance in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecium healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational study

The Lancet Regional Health - Americas
Summary Background Carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE) are listed by World ...
L. Antochevis, C. Wilhelm, Beatriz Arns, D. Sganzerla, L. Sudbrack, Thais C.R.L. Nogueira, R. D. Guzman, A. Martins, Dan Cappa, A. C. dos Santos, J. Pascual, Vitor Hugo Perugini, E. Vespero, M. H. Rigatto, D. C. Pereira, Larissa Lutz, R. Leão, Elizabeth A. Marques, D. M. Henrique, A. Coelho, L. L. Frutuoso, Erika E. de A Sousa, Luiz F. Abreu Guimarães, Adriana Lúcia Pires Ferreira, A. C. Castiñeiras, M. Alves, J. P. Telles, C. Yamada, Francieli P. de Almeida, E. Girão, Paulo C.P. de Sousa, Antonio G.N.D. de Melo, E. Mendes, V. Rocha, E. D. S. Neves, Marcello T. Ribeiro, C. E. Starling, M. S. Oliveira, Jorge L. M. Sampaio, A. F. Martins, A. Barth, A. Zavascki, Jéssica Nesello dos Santos, C. F. Ferreira, T. Vieceli, Julival Ribeiro Fagundes, R. Matias, Shisue Karina Katagiri, O. Neto, Rafaela Kuczynski da Rocha, Cláudia Carrilho, M.E. Mauro de Almeida, H. Rosa, Valéria Paes Lima, Tazio Vanni, S. Nouér, Elizabeth Mendes Alves, J. Rodrigues, André Jhonathan Dantas, Gyselle de Souza Rebouças, J. de Oliveira   +60 more
semanticscholar   +1 more source

Trends in Enterobacterales Bloodstream Infections in Children

Pediatrics
OBJECTIVES Enterobacterales bloodstream infections (E-BSI) cause a significant burden of disease in children and are associated with antimicrobial resistance. We assessed temporal changes in the population-based incidence of E-BSI in children in Queensland, Australia.
Gibbs, Anna A.M., Laupland, Kevin B., Edwards, Felicity, Ling, Weiping, Channon-Wells, Samuel, Harley, David, Falster, Kathleen, Paterson, David L., Harris, Patrick N.A., Irwin, Adam D.   +9 more
openaire   +5 more sources

Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017–2022)

Open Forum Infectious Diseases
Background Carbapenem-resistant Enterobacterales (CREs) are a major public health threat because treatment options are limited. The predominant resistance mechanism in CREs is the production of carbapenemases.
K. Papp-Wallace, H. Sader, Joshua M. Maher, J. Kimbrough, M. Castanheira   +4 more
semanticscholar   +1 more source

Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019–2023)

Journal of Antimicrobial Chemotherapy
Objectives To evaluate the in vitro activity of aztreonam/avibactam against Enterobacterales from European medical centres during the 5-year period prior to its approval for clinical use in Europe.
H. Sader, J. Kimbrough, Marisa L. Winkler, M. Castanheira, R. Mendes   +4 more
semanticscholar   +1 more source